

CEO Fredrik Alpsten leaves Devyser and Fredrik Dahl is appointed new acting CEO of Devyser

Fredrik Alpsten and the Board of Directors of Devyser have now reached an agreement that he will leave his position as CEO of Devyser.

Devyser's Board of Directors has initiated the recruitment of a new CEO. Fredrik Dahl, PhD in Molecular Medicine, currently a board member and well acquainted with the company, has been appointed acting CEO.

The Board of Directors would like to thank Fredrik for his appreciated efforts among both employees, customers and investors. In order to continue developing the company's full potential and increase profitability, the Board of Directors now desires a new leadership.

Devyser - which has seen rapid growth and expanded its international business - remains committed to its strategy going forward.

Fredrik Dahl holds a PhD in Molecular Medicine from Uppsala University and has done research at Stanford University in DNA technology. After his studies at Stanford, Fredrik worked in California at a pioneering research company in DNA sequencing. Thereafter he moved back to Sweden and co-founded Halo Genomics, which was sold to the American Agilent Technologies, and co-founded Vanadis Diagnostics, which was sold to the American diagnostics company PerkinElmer (now Revvity). Fredrik Dahl thus has extensive international experience in various management roles from global research and diagnostics companies.

Fredrik Dahl will remain as a member of Devyser's Board of Directors.

For more information, please contact

Mia Arnhult, Chairman of the Board of Directors, tel. +46 70-769 82 46

Fredrik Dahl, acting CEO, tel. +46 73-091 74 40



PRESS RELEASE

16 January 2025 11:15:00 CET

About Devyser

Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 65 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.

Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.

Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.

For more information, visit www.devyser.com.

This information is information that Devyser Diagnostics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2025-01-16 11:15 CET.